World's Best Scientists 2026 revealed!
Alexander M.M. Eggermont

Alexander M.M. Eggermont

D-Index & Metrics

Medicine

D-Index
144
Citations
103864
World Ranking
1412
National Ranking
31

Alexander M.M. Eggermont publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alexander M.M. Eggermont sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 866 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alexander M.M. Eggermont D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alexander M.M. Eggermont sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 144 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alexander M.M. Eggermont is affiliated with the Institut Gustave Roussy in France. Their research primarily focuses on the field of Medicine, with significant contributions specifically in Oncology, Immunology, Molecular Biology, Epidemiology, and Pulmonary and Respiratory Medicine.

The scientist's work spans several main topics, including:

  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Nonmelanoma Skin Cancer Studies
  • Cancer Genomics and Diagnostics

Alexander M.M. Eggermont has published extensively in prominent venues. The most frequent publication venues include:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • The Lancet Oncology
  • Annals of Oncology
  • Molecular Oncology

Frequent co-authors in their research include:

  • Georgina V. Long
  • Paolo A. Ascierto
  • Caroline Robert
  • Dirk Schadendorf
  • Mario Mandalà

Some of the recent papers authored or co-authored by Alexander M.M. Eggermont include:

  • "Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo," 2020, JAMA Oncology
  • "Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial," 2020, Journal of Clinical Oncology
  • "The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes," 2020, Cancer Cell (authored by Floris Dammeijer as primary author with Eggermont likely involved)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment," 2020, European Journal of Cancer (Authored by Alexander Stratigos)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention," 2020, European Journal of Cancer (Authored by Alexander J. Stratigos)

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

  • Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

    Marie Vétizou;Marie Vétizou;Marie Vétizou;Jonathan M. Pitt;Jonathan M. Pitt;Jonathan M. Pitt;Romain Daillère;Romain Daillère;Romain Daillère;Patricia Lepage

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

    J.M. Pitt;A. Marabelle;A. Marabelle;A. Eggermont;J.-C. Soria

  • Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

    N. Chaput;P. Lepage;C. Coutzac;C. Coutzac;E. Soularue;E. Soularue

  • Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

    Stephane Champiat;Stephane Champiat;Laurent Dercle;Samy Ammari;Christophe Massard

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

    Celine Boutros;Ahmad Tarhini;Emilie Routier;Olivier Lambotte

  • Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba

  • TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

    Remco van Horssen;Timo L. M. ten Hagen;Alexander M. M. Eggermont

  • Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

    S. Champiat;S. Champiat;O. Lambotte;E. Barreau;R. Belkhir

  • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

    Chong Sun;Liqin Wang;Sidong Huang;Guus J. J. E. Heynen

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

Frequent Co-Authors

Caroline Robert
Caroline Robert University of Paris-Saclay
Stefan Suciu
Stefan Suciu European Organisation for Research and Treatment of Cancer
Guido Kroemer
Guido Kroemer Université Paris Cité
Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Lorenzo Galluzzi
Lorenzo Galluzzi Cornell University
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Axel Hauschild
Axel Hauschild Kiel University
Ulrich Keilholz
Ulrich Keilholz Charité - University Medicine Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees and career pathways can offer flexible entry points into the medical field in the USA. If you're interested in becoming a nurse but hold a bachelor’s degree in another subject, consider msn direct entry programs online designed for non-nurses. These accelerated master's programs allow you to qualify as a registered nurse in less time.

For students seeking accessible options, there are nursing programs with high acceptance rates. These can be a practical starting point if competitive admissions are a concern. Additionally, financial and entrance exam barriers can be minimized by looking for absn programs that don't require teas, opening opportunities for more prospective students.

Interested in healthcare administration? Explore accredited medical billing and coding schools online with financial aid to gain essential skills for this growing field. Each of these pathways can help you carve out a rewarding career in healthcare while allowing for greater flexibility and accessibility.

Best Scientists Citing Alexander M.M. Eggermont

Trending Scientists

Recently Published Articles